BRAF and neoplasm: In BRAF-mutant melanoma, pharmacologic induction of gasdermin D/E-mediated pyroptosis has demonstrated synergy with BRAF/MEK inhibition in resistant models, eliciting immunogenic cell death and potentiating anti-tumor immunity (39).